AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02039284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRCIT
Description: VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
Study NCT02039284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation program
Description: The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
Study NCT03499314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active RS-tDCS +At-Home Manual Dexterity Training
Description: Bilateral M1-SO electrode placement; Active= anodal 2.0 mA dose × 20 minutes
Study NCT03499314 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham RS-tDCS +At-Home Manual Dexterity Training
Description: Designed to ensure blinding, includes initial and ending ramp-up/down stimulation for 60 seconds
Study NCT03499314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual dexterity training
Description: Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.
Study NCT03499314 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Manual dexterity training
Description: Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.
Study NCT02583295 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music sound
Description: The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
Study NCT02583295 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maternal sound
Description: The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
Study NCT01867502 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MET + Vildagliptin Group
Description: Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.~For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator.
Study NCT01867502 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MET + Glibenclamide Group
Description: The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator.
Study NCT02466984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide intravenous
Description: Administration route
Study NCT02466984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide intravenous
Description: Administration route
Study NCT05062135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 400 Mg Vaginal Suppository on PCOS
Description: The same drug will be used in control group
Study NCT03295760 — intervention group
Intervention type: DRUG
Intervention: Q10 Coenzyme
Study NCT00931606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: up to 4 subcutaneous doses of sotatercept given once every 28 days
Study NCT00004918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02657811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miri, Benchtop Multi-room incubator
Description: Bench Incubation - Morphologic Assessment These embryos will undergo multiple evaluations using light microscopy and traditional morphologic assessment.
Study NCT02657811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miri TL, Time-Lapse incubator
Description: Time Lapse Incubation - Morphologic/Morphokinetic Assessment These embryos will remain in the TLI and undergo both morphologic and morphokinetic evaluation and grading according to a hierarchical multivariable model. They will not be removed from incubation for the duration of culture.
Study NCT02657811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miri TL, Time-Lapse incubator
Description: Time Lapse Incubation - Morphologic Assessment These embryos will remain in the TLI and undergo only traditional morphologic assessment according to accepted criteria with no additional imaging. They will also not be removed from incubation for the duration of culture. The time points and evaluated parameters will be identical to those in arm 1 of the study.
Study NCT04369248 — intervention group
Intervention type: OTHER
Intervention: hepassocin
Description: hepassocin levels in polycystic ovary syndrome
Study NCT03325907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: navigational template
Description: The navigational template was created based on computed tomography data using three-dimensional technology.
Study NCT01703637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: * before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy
Study NCT01703637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: * before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy
Study NCT01703637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: * before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~* before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy
Study NCT03484858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High glycaemic index meal and exercise
Study NCT03484858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High glycaemic index meal and rest
Study NCT03484858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low glycaemic index meal and exercise
Study NCT02045771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce antidepressant behaviour (Martell, Dimidjian et al. 2010).
Study NCT02045771 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Support Group
Description: In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
Study NCT03492697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 Immediate Release Tablet
Description: Immediate Release Tablet
Study NCT03492697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 Controlled Release Tablet (long)
Description: Controlled Release tablet (long)
Study NCT03492697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 Controlled Release Tablet (short)
Description: Controlled Release tablet (short)
Study NCT03484858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low glycaemic index meal and rest
Study NCT01716442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
Study NCT01716442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02147132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Nasal Spray
Description: 7 days. 1 mg/dose, up to 40x/day.
Study NCT03492697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 Immediate Release Solution
Description: PF-06882961 Immediate Release solution
Study NCT03735862 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hepatic derived surgical matrix
Description: Hiatal hernia repair with MIROMESH
Study NCT01524770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered by subcutaneous (SC) injection
Study NCT01524770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered by subcutaneous (SC) injection
Study NCT02322554 — intervention group
Intervention type: BIOLOGICAL
Intervention: Cellular and tissue based products
Description: Procedure: Application of device or biological to wounds
Study NCT02214277 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cerebral Protection System-The SENTINEL System with TAVR
Description: Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
Study NCT02214277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral Protection System-The SENTINEL System with TAVR
Description: Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
Study NCT02214277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR
Study NCT01392950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua
Description: Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
Study NCT01392950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clariti
Description: Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
Study NCT00858871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brivanib
Description: Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
Study NCT00858871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
Study NCT00858871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
Study NCT00858871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
Study NCT03317509 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic (rTMS)
Description: Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
Study NCT02147132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
Study NCT03599440 — intervention group
Intervention type: OTHER
Intervention: Pressure line extensions
Description: Two types of extension lines are connected:~* Perfusor® line 150cm (polyethylene)~* conventional arterial extension line
Study NCT02634528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Julphar Insulin N (human isophane insulin)
Description: investigational insulin: Julphar N (human isophane insulin), biosimilar
Study NCT02634528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huminsulin® Basal (NPH, human isophane insulin)
Description: marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
Study NCT04162977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted Interventions
Description: The Personality-targeted Interventions (i.e., Preventure programme) are selective substance use prevention programme designed to target known personality risk factors for substance misuse based on the evidence from cross-sectional and longitudinal studies which connect these personality risk factors to early initiation and escalation of substance misuse in adolescents. This selected personality-targeted approach targets four personality-specific motivational pathways to substance misuse: Hopelessness, Anxiety Sensitivity, Impulsivity, and Sensation Seeking. Each intervention will involve two 90-minute sessions, with an average of 6 personality-matched adolescents per group, and will be conducted using manuals that incorporate psycho-educational, motivational enhancement therapy (MET), and cognitive behavioural therapy (CBT) components and include real life 'scenarios' shared by high-risk local youth with similar personality profiles.
Study NCT00856453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home yoga practice
Description: training for and tracking of patient's practice of yoga at home
Study NCT00856453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga classes
Description: organized out of home classes for yoga
Study NCT02147132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: 7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
Study NCT02465866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108
Description: Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth
Study NCT02465866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicoprofen
Description: Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth
Study NCT02465866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet
Description: Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth
Study NCT02465866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenergan
Description: Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth
Study NCT05038319 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: EUS
Description: The procedures would be performed by a therapeutic endoscope with the through the scope method. The endoscope would be used to reach the site of Varices.
Study NCT05038319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: The procedures would be performed by a therapeutic endoscope with the through the scope method. The endoscope would be used to reach the site of Varices.
Study NCT02147132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Varenicline
Description: 14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
Study NCT02732470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qi Gong
Description: The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
Study NCT02326493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy
Description: A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
Study NCT03964272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate Bilateral Subthalamotomy
Description: Exablate bilateral treatment for Parkinson's Disease Motor Features
Study NCT02475707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiTAA-specific T cells
Description: The 3 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients being treated on Arm A (adjuvant) or Arm B (active disease) who have a partial response, complete response or stable disease, will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions at a minimum of 4 weeks apart.
Study NCT01946750 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Whole blood
Description: Optional sample collected for the cases and non-diarrheal control at the same time as the serum, in order to study cellular immunity and describe the determinants of the development of a protective adaptive response.
Study NCT03745209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Use of real-time ultrasound in an attempt to establish intravenous peripheral catheter.
Study NCT03062852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication safety vest
Description: The nurses preparing and administering medication will wear a medication safety vest. On the back of the vest, the sentance Do not disturb me. I am preparing medications is written to inform others professional, patients and visitors. A informational flyer will be put in the units to inform patients and visitors about the intervention.
Study NCT02992743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letetresgene autoleucel (GSK3377794)
Description: Letetresgene autoleucel (GSK3377794) as an IV infusion.
Study NCT02992743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Study NCT02992743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as a lymphodepleting chemotherapy.
Study NCT00677066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy
Description: Administer oxygen at home or in hospital
Study NCT02835794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
Study NCT02835794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
Study NCT02835794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
Study NCT03229902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mantra meditation
Description: see study description
Study NCT03195946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: tablets for oral use, 10 mg/day
Study NCT03195946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: syrup for oral use, 4mg/day
Study NCT03195946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail of CYP450 substrates
Description: Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day